<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03819101</url>
  </required_header>
  <id_info>
    <org_study_id>2017-004639-35</org_study_id>
    <secondary_id>2017/2601</secondary_id>
    <nct_id>NCT03819101</nct_id>
  </id_info>
  <brief_title>Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer</brief_title>
  <acronym>PEACE-4</acronym>
  <official_title>A Phase III Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2x2 factorial randomized, multicenter, international, open phase III trial.

      The primary objective is to evaluate the benefit of acetylsalicylic acid and atorvastatin on
      overall survival (OS) (main endpoint) for patients with castrate-resistant prostate cancer
      starting first line treatment for CRPC
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2019</start_date>
  <completion_date type="Anticipated">March 2038</completion_date>
  <primary_completion_date type="Anticipated">March 2034</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>This is a 2x2 factorial randomized, multicenter, international, open phase III trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>OS will be calculated from the date of randomization to the date of death up to 15 years</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1210</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care (SOC) for CRPC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SOC + acetylsalicylic acid 100 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SOC + atorvastatin 80 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SOC + acetylsalicylic acid 100 mg daily + atorvastatin 8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <description>100mg</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>80 mg</description>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the prostate and no curative local therapy
             considered possible

          -  Age ≥ 18 years, life expectancy of at least 6 months

          -  CRPC defined as tumor progression (PSA increase on at least 2 separate values
             separated by at least 1 week or progression on imaging) while on Androgen Deprivation
             Therapy (orchiectomy, LHRH agonist or -antagonist) with documented serum testosterone
             levels ≤ 1.7 nmol/L (≤ 0.50 ng/mL). Ongoing concurrent use of LHRH agonist or
             antagonist is required if the patient has not been surgically castrated

          -  Presence (M1) or absence (M0) of metastases on imaging

          -  Performance status 0, 1 or 2

          -  No previous use of life- prolonging treatments for CRPC (including abiraterone,
             enzalutamide, radium-223, docetaxel, cabazitaxel, and sipuleucel-T). The use of these
             agents together with Androgen Deprivation Therapy (ADT) for castrate-sensitive disease
             is allowed.

          -  Adequate renal function within 30 days prior to registration: calculated creatinine
             clearance ≥ 50 mL/min, according to the formula of Cockcroft-Gault and adequate liver
             function with levels of AST and ALT ≤ 3xULN and no signs for cholestasis.

          -  Participation in other clinical trials is allowed except for trials with the same
             primary endpoint, i.e. OS

          -  Patient authorized to participate to a clinical trial by specific country regulation
             (eg patient affiliated to a social security system or beneficiary of the same)

          -  Information delivered to patient and informed consent form signed by the patient.

        Exclusion Criteria:

          -  Previous localised malignancy within 2 years with the exception of localized
             non-melanoma skin cancer and Ta or Tis bladder cancer (patients with asymptomatic
             Chronic Lymphoïd Leukemia can be included)

          -  Previous metastatic malignancy within 5 years

          -  Patient currently taking daily acetylsalicylic acid or a daily statin within the last
             6 months

          -  Patients with active liver disease (hepatitis B or C, cirrhosis) or unexplained
             persistent elevations of serum transaminases exceeding 3 times the upper limit of
             normal or cholestasis

          -  Patients with excessive alcohol intake or history of a relevant liver disease

          -  Known hypersensitivity or intolerance to acetylsalicylic acid or atorvastatin or
             hypersensitivity to any of its components

          -  Contra-indication to acetylsalicylic acid or atorvastatin according to label,
             including known high-risk for haemorrhage,

          -  History of or active myopathy or significantly elevated (&gt; 5 times ULN) CK levels

          -  History of recent stroke or transient ischemic attack (TIA).

          -  Any concomitant drugs contraindicated for use with the trial drugs according to the
             product information (e.g. Fucidic acid, potent inhibitors of CYP3A4 or transport
             proteins: ciclosporine, telithromycin, clarithromycin, delavirdine, stiripentol,
             ketoconazole, voriconazole, itraconazole, posaconazole and HIV protease inhibitors
             including ritonavir, lopinavir, atazanavir, indinavir, darunavir, tripanavir,
             telaprevir, saquinavir, darunavir, fosamprenavir, boceprivir, gemfibrozil,
             fenofibrate, etc)

          -  Any serious underlying medical condition (by the investigator's judgement) which could
             impair the ability of the patient to participate in the trial

          -  Patients with hereditary galactose intolerance, Lapp-lactase deficiency or
             Glucose-Galactose-malabsorption

          -  Compliance with trial medical follow-up impossible due to geographic, social or
             psychological reasons

          -  Psychiatric disorder precluding understanding of information about trial related
             topics, providing informed consent, or interfering with compliance for oral drug
             intake
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Prostate cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karim Fizazi, MD, PhD</last_name>
    <phone>0142114317</phone>
    <phone_ext>+33</phone_ext>
    <email>karim.fizazi@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gwenael Le Teuff</last_name>
    <phone>0142114955</phone>
    <phone_ext>+33</phone_ext>
    <email>gwenael.leteuff@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy Cancer Campus Grand Paris</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Karim Fizazi, MD, PhD</last_name>
      <phone>0142114317</phone>
      <phone_ext>+33</phone_ext>
      <email>karim.fizazi@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Anne Sophie Hue</last_name>
      <phone>0142113890</phone>
      <phone_ext>+33</phone_ext>
      <email>anne-sophie.hue@gustaveroussy.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 24, 2019</study_first_submitted>
  <study_first_submitted_qc>January 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2019</study_first_posted>
  <last_update_submitted>January 25, 2019</last_update_submitted>
  <last_update_submitted_qc>January 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

